Q99. Match the therapeutic factors in Column I with the application in Column II
| Column I | Column II |
|---|---|
| P. Humin | (1) Cancer therapy |
| Q. Erythropoietin | (2) Diabetes |
| R. Thrombopoietin | (3) Osteoporosis |
| S. Leptin | (4) Anemia |
| T. Calcitonin | (5) Myocardial infarction |
| (6) Obesity |
(A) P–(ii), Q–(iv), R–(v), S–(iii), T–(vi)
(B) P–(ii), Q–(v), R–(i), S–(iv), T–(iii)
(C) P–(v), Q–(vi), R–(iv), S–(iii), T–(i)
(D) P–(iii), Q–(iv), R–(ii), S–(v), T–(vi)
The correct answer is (C) P-5, Q-4, R-1, S-6, T-3.
Humin, a human albumin preparation, treats hypovolemia often linked to myocardial infarction complications like shock or trauma. Erythropoietin addresses anemia in chronic kidney disease and chemotherapy patients. Thrombopoietin manages thrombocytopenia in cancer therapy to support chemotherapy continuation.
Matching Details
-
P. Humin → (5) Myocardial infarction: Human albumin (Humin) restores blood volume in hypovolemic shock post-myocardial infarction, surgery, or trauma.
-
Q. Erythropoietin → (4) Anemia: Stimulates red blood cell production for anemia from kidney disease or chemotherapy.
-
R. Thrombopoietin → (1) Cancer therapy: Boosts platelet counts to counter chemotherapy-induced thrombocytopenia.
-
S. Leptin → (6) Obesity: Regulates appetite and energy balance; used in leptin-deficient obesity cases.
-
T. Calcitonin → (3) Osteoporosis: Inhibits bone resorption to treat postmenopausal osteoporosis and Paget’s disease.
Option Analysis
Option (A) mismatches Humin (5, not 2), Erythropoietin (4, not 4? Wait, but others wrong), Leptin (6, not 3), and Calcitonin (3, not 6). Incorrect.
Option (B) errs on Humin (5, not 2), Erythropoietin (4, not 5), Thrombopoietin (1, not 1? But others fail), Leptin (6, not 4). Incorrect.
Option (C) correctly pairs all as above. Correct.
Option (D) misassigns Humin (5, not 3), Thrombopoietin (1, not 2), Leptin (6, not 5). Incorrect.
Introduction to Therapeutic Proteins in Medicine
Therapeutic factors like Humin (human albumin), Erythropoietin, Thrombopoietin, Leptin, and Calcitonin play crucial roles in treating conditions from anemia to osteoporosis. These biologics, often recombinant or purified proteins, target specific deficiencies in CSIR NET Life Sciences contexts. Understanding their matches aids exam success and biotech knowledge.
Key Applications Breakdown
-
Humin in Myocardial Infarction: Replaces lost fluids post-heart attack, stabilizing volume in shock.
-
Erythropoietin for Anemia: Boosts erythropoiesis in renal or chemo-induced cases.
-
Thrombopoietin in Cancer Therapy: Prevents thrombocytopenia during chemotherapy.
-
Leptin Targets Obesity: Restores satiety signaling in deficiency states.
-
Calcitonin Manages Osteoporosis: Reduces osteoclast activity for bone density.
Exam Relevance for CSIR NET
This matching tests biotech applications in endocrinology and hematology. Focus on clinical uses: albumin for hypovolemia (MI-related), EPO for RBCs, TPO for platelets in oncology. Practice reveals (C) as optimal.
Clinical Insights and Safety
These agents show favorable profiles but require monitoring—e.g., thrombosis risk with TPO mimetics. Advances include TPO receptor agonists for sustained efficacy in cancer patients.
